Clinical Trials
21 trialsNCT07466238 2026-05-08
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
Phase NA Recruiting
NCT06190275 2026-04-24
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
Grit Biotechnology
Phase NA Recruiting
NCT07427186 2026-02-25
MINER2
Institut Claudius Regaud
Phase NA Not yet recruiting
NCT07428252 2026-02-25
Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma
Institute of Oncology Ljubljana
Phase NA Active not recruiting
NCT03514368 2026-02-19
MINER
Institut Claudius Regaud
Phase NA Recruiting
NCT06248554 2025-12-02
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
Tongji Hospital
Phase NA Recruiting
NCT06740370 2025-08-14
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Recruiting
NCT07101536 2025-08-03
The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)
West China Hospital
Phase NA Not yet recruiting
NCT07067450 2025-07-16
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Phase NA Not yet recruiting
NCT05754203 2025-07-14
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
Xinqiao Hospital of Chongqing
Phase NA Recruiting
NCT06991907 2025-05-28
PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety
Jiangxi Provincial Cancer Hospital
Phase NA Completed
NCT06622031 2025-01-13
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Sun Yat-sen University
Phase NA Recruiting
NCT06752044 2024-12-30
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT06752057 2024-12-30
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT06708650 2024-11-27
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
Guiping People's Hospital
Phase NA Not yet recruiting
NCT06702566 2024-11-25
The Effect of Serum Ferritin in irAE
Tianjin Medical University Cancer Institute and Hospital
Phase NA Recruiting
NCT05878977 2024-10-18
Biomarkers in Immunotherapy of Melanoma
Institute of Oncology Ljubljana
Phase NA Recruiting
NCT04891900 2024-07-08
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Phase NA Active not recruiting
NCT05248022 2024-01-09
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05001360 2021-10-27
Study of FMT Combined With Nivolumab in Gastric Cancer
Fujian Cancer Hospital
Phase NA Withdrawn